微小肝癌早期诊断关键分子的研究进展

杨静; 曹宪炳; 连镇炎; 周旭洋; 张诗雨; 曾宁; 方驰华

doi:10.12122/j.issn.1674-4500.2020.04.14

微小肝癌早期诊断关键分子的研究进展

doi: 10.12122/j.issn.1674-4500.2020.04.14

杨静^1,,
曹宪炳¹,
连镇炎¹,
周旭洋¹,
张诗雨¹,
曾宁^2,, ,,
方驰华^2,, ,

1.
南方医科大学第二临床医学院，广东广州 510282
2.
广东省数字医学临床工程技术研究中心，广东广州 510282

基金项目:

“十二五”国家高技术研究发展（863）计划 2012AA021105

南方医科大学2019年校级大学生创新训练计划项目资助 201912121241

NSFC-广东联合基金项目 U1401254

广东省科技计划 2016ZC0082

“十三五”国家重点研发计划数字诊疗装备研发重点专项 2016YFC0106500

广州市科技计划 201604020144

国家自然科学基金重大仪器项目 81627805

详细信息

作者简介:
杨静，本科，E-mail: 819106172@qq.com

通讯作者:
曾宁，博士，副主任医师，E-mail: chen_ning16@foxmail.com

方驰华，博士，主任医师，E-mail: fangch_dr@126.com

计量
- 文章访问数: 526
- HTML全文浏览量: 346
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-15
- 刊出日期: 2020-10-20

Study on the key molecules in early diagnosis of micro hepatocellular carcinoma

1.
The Second Clinical Medical College, Southern Medical University, Guangzhou 510282, China
2.
Digital-medicine Clinical Engineering Technology Research Center of Guangdong, Guangzhou 510282, China

摘要

摘要: 肝癌是消化系统的常见恶性肿瘤之一，因大多数患者在肝癌早期并无临床症状，在就诊时已多是晚期，死亡率高特点决定了早期诊断和早期治疗是提高生存率最有效手段。如何提高微小肝癌的早期诊断成为我们亟待解决的重要问题，而微小肝癌早期新生血管关键分子则成为早期诊断至关重要的一步。本文通过查阅近几年国内外相关文献，对部分微小肝癌早期诊断关键分子-Prox1、Glypican-3、上皮细胞黏附因子、趋化因子受体4的研究现状和不足进行综述，旨在为微小肝癌的早期筛查和诊断提供的新方向及思路。
- 微小癌灶 /
- 早期诊断 /
- 肝癌 /
- 关键分子 /
- 肿瘤标志物
Abstract: Liver cancer is one of the common malignant tumors of the digestive system. Most patients have no clinical symptoms in the early stages of liver cancer and are mostly advanced at the time of consultation. The high mortality rate determines that early diagnosis and early treatment are the most effective methods to improve survival rate.Therefore, how to improve the early diagnosis of minimal liver cancer has become an urgent issue that we need to solve. The key molecules of early neovascularization of micro hepatocellular carcinoma have become a very important step in early diagnosis. Therefore, by reviewing relevant domestic and foreign literature in recent years, this article studied four key molecules of early diagnosis of micro hepatocellular like carcinoma-Prox1, Glypican-3, EpCAM, CXCR4. The current situation and deficiencies were reviewed in order to provide new directions and ideas for the early screening and diagnosis of minimal liver cancer.
- microcarcinoma /
- early diagnosis /
- liver cancer /
- key molecules /
- tumor markers

HTML全文

参考文献(37)

[1]	Global burden of disease cancer collaboration, Fitzmaurice C, Akinyemiju TF, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2018, 4(11): 1553-68. doi: 10.1001/jamaoncol.2018.2706
[2]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA:ACancer J Clin, 2015, 65(2): 87-108. doi: 10.3322/caac.21262
[3]	Zinovieva RD, Duncan MK, Johnson TR, et al. Structure and chromosomal localization of the human homeobox gene Prox 1[J]. Genomics, 1996, 35(3): 517-22. doi: 10.1006/geno.1996.0392
[4]	任雷.原发性肝癌中Prox1蛋白的表达及临床意义[D].苏州: 苏州大学, 2015.
[5]	Liu YF, Zhang YL, Wang SH, et al. Prospero- related homeobox 1 drives angiogenesis of hepatocellular carcinoma through selectively activating interleukin-8 expression[J]. Hepatology, 2017, 66(6): 1894-909. doi: 10.1002/hep.29337
[6]	王静文.肿瘤细胞Annexin A7调控对淋巴管内皮细胞VEGF-C/D— VEGFR-3/NRP-2及淋巴管相关分子的影响[D].大连: 大连医科大学, 2018.
[7]	Teng HM, Yang YZ, Wei HY, et al. Fucoidan suppresses hypoxiainduced lymphangiogenesis and lymphatic metastasis in mouse hepatocarcinoma[J]. Mar Drugs, 2015, 13(6): 3514-30. doi: 10.3390/md13063514
[8]	张巨波, 叶青海.转录因子PROX1调节HIF-1a表达促进肝细胞肝癌侵袭转移的机制研究[C].中国抗癌协会.第十届全国肿瘤转移学术大会论文集, 2013: 1-2.
[9]	Lee JH. Analysis of the cancer genome atlas data to determine the correlation between PROX1 and TERT in hepatocellular carcinoma [J]. Int J Cancer, 2019, 144(7): 1752-3. doi: 10.1002/ijc.31888
[10]	Kim YJ, Yoo JE, Jeon Y, et al. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma[J]. Int J Cancer, 2018, 143(12): 3155-68. doi: 10.1002/ijc.31731
[11]	Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma[J]. Semin Oncol, 2012, 39(4): 434-9. doi: 10.1053/j.seminoncol.2012.05.009
[12]	Tahon AM, El-Ghanam MZ, Zaky S, et al. Significance of glypican-3 in early detection of hepatocellular carcinoma in cirrhotic patients [J]. J Gastrointest Cancer, 2019, 50(3): 434-41. doi: 10.1007/s12029-018-0095-2
[13]	吴孟超, 汤钊猷, 刘彤华, 等.原发性肝癌规范化病理诊断指南(2015年版)[J].临床肝胆病杂志, 2015, 31(6): 833-9. doi: 10.3969/j.issn.1001-5256.2015.06.004
[14]	中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版) [J].消化肿瘤杂志:电子版, 2017, 9(4): 213-28.
[15]	Abdelgawad IA, Mossallam GI, Radwan NH, et al. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?[J].Asian Pac J Cancer Prev, 2013, 14(12): 7345-9. doi: 10.7314/APJCP.2013.14.12.7345
[16]	Aghemo A. Update on HCC management and review of the new EASLguidelines[J]. Gastroenterol Hepatol (NY), 2018, 14(6): 384-6. http://www.researchgate.net/publication/327369636_Update_on_HCC_Management_and_Review_of_the_New_EASL_Guidelines
[17]	Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(1): 275-83. doi: 10.3748/wjg.v22.i1.275
[18]	Li B, Liu H, Shang HW, et al. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients[J]. Afr Health Sci, 2013, 13(3): 703-9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824453/?report=classic
[19]	Qi XH, Wu D, Cui HX, et al. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells[J]. Mol Med Rep, 2014, 10(6): 3177-84. doi: 10.3892/mmr.2014.2600
[20]	Capurro M, Martin T, Shi W, et al. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling[J]. J Cell Sci, 2014, 127(Pt 7): 1565-75. http://www.ncbi.nlm.nih.gov/pubmed/24496449
[21]	Tremosini S, Forner A, Boix L, et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma[J]. Gut, 2012, 61(10): 1481-7. doi: 10.1136/gutjnl-2011-301862
[22]	Hanaoka H, Nakajima T, Sato K, et al. Photoimmunotherapy of hepatocellular carcinoma- targeting Glypican-3 combined with nanosized albumin- bound paclitaxel[J]. Nanomedicine (Lond), 2015, 10(7): 1139-47. doi: 10.2217/nnm.14.194
[23]	吕桂帅, 陈磊, 王红阳.我国肝癌研究的现状与前景[J].生命科学, 2015, 27(3): 237-48. http://www.cqvip.com/QK/97031A/20153/664364018.html
[24]	Huch M, Dollé L. The plastic cellular states of liver cells: Are EpCAM and Lgr5 fit for purpose?[J]. Hepatology, 2016, 64(2): 652- 62. doi: 10.1002/hep.28469
[25]	Yang J, Isaji T, Zhang GW, et al. EpCAM associates with integrin and regulates cell adhesion in cancer cells[J]. Biochem Biophys Res Commun, 2020, 522(4): 903-9. doi: 10.1016/j.bbrc.2019.11.152
[26]	秦建民.肝细胞癌切除术后复发的原因与防治策略[J].世界华人消化杂志, 2019, 27(23): 1407-18. http://www.cqvip.com/QK/98142X/201923/7100440561.html
[27]	刘广欣, 党立力, 黄启科, 等.肝癌干细胞的研究进展[J].现代肿瘤医学, 2013, 21(9): 2123-7. doi: 10.3969/j.issn.1672-4992.2013.09.71
[28]	Locatelli E, Li Y, Monaco I, et al. A novel theranostic gold nanorodsand Adriamycin-loaded micelle for EpCAM targeting, laser ablation, and photoacoustic imaging of cancer stem cells in hepatocellular carcinoma[J]. Int J Nanomedicine, 2019, 14: 1877-92. doi: 10.2147/IJN.S197265
[29]	Yamashita T, Ji JF, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features[J]. Gastroenterology, 2009, 136(3): 1012-24. doi: 10.1053/j.gastro.2008.12.004
[30]	李妍晨, 华宗荣, 刘瑶, 等. CXCL12-CXCR4/CXCR7生物轴在肝癌中的研究进展[J].肿瘤防治研究, 2017, 44(9): 636-40. doi: 10.3971/j.issn.1000-8578.2017.17.0291
[31]	Abraham M, Klein S, Bulvik B, et al. The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL- 2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression[J]. Leukemia, 2017, 31(11): 2336-46. doi: 10.1038/leu.2017.82
[32]	Taromi S, Kayser G, Catusse J, et al. CXCR4 antagonists suppress small cell lung cancer progression[J]. Oncotarget, 2016, 7(51): 85185-95. doi: 10.18632/oncotarget.13238
[33]	Waldmann TA. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics [J]. Mol Cell Endocrinol, 2017, 451: 66-70. doi: 10.1016/j.mce.2017.02.019
[34]	Xu J, Liang J, Meng YM, et al. Vascular CXCR4 expression promotes vessel sprouting and sensitivity to sorafenib treatment in hepatocellular carcinoma[J]. Clin Cancer Res, 2017, 23(15): 4482- 92. doi: 10.1158/1078-0432.CCR-16-2131
[35]	Shen XH, Li N, Li H, et al. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2010, 136 (11): 1745-54. doi: 10.1007/s00432-010-0833-8
[36]	Tan AT, Schreiber S. Adoptive T-cell therapy for HBV- associated HCC and HBV infection[J].Antiviral Res, 2020, 176: 104748. doi: 10.1016/j.antiviral.2020.104748
[37]	Tan AT, Yang NH, Lee Krishnamoorthy T, et al. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy[J]. Gastroenterology, 2019, 156(6): 1862-76. doi: 10.1053/j.gastro.2019.01.251

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 526
HTML全文浏览量: 346
PDF下载量: 5
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

微小肝癌早期诊断关键分子的研究进展

doi: 10.12122/j.issn.1674-4500.2020.04.14

作者简介:
杨静，本科，E-mail: 819106172@qq.com

通讯作者:
曾宁，博士，副主任医师，E-mail: chen_ning16@foxmail.com

方驰华，博士，主任医师，E-mail: fangch_dr@126.com

计量

Study on the key molecules in early diagnosis of micro hepatocellular carcinoma

计量

目录

留言板

微小肝癌早期诊断关键分子的研究进展

doi: 10.12122/j.issn.1674-4500.2020.04.14

作者简介: 杨静，本科，E-mail: 819106172@qq.com

通讯作者: 曾宁，博士，副主任医师，E-mail: chen_ning16@foxmail.com 方驰华，博士，主任医师，E-mail: fangch_dr@126.com

计量

出版历程

Study on the key molecules in early diagnosis of micro hepatocellular carcinoma

计量

出版历程

目录

作者简介:
杨静，本科，E-mail: 819106172@qq.com

通讯作者:
曾宁，博士，副主任医师，E-mail: chen_ning16@foxmail.com

方驰华，博士，主任医师，E-mail: fangch_dr@126.com